maraviroc + saquinavir + ritonavir

A combination of **maraviroc**, **saquinavir**, and **ritonavir** used for the treatment of HIV-1 infection. Maraviroc is a small molecule antagonist of the CCR5 receptor, blocking HIV-1 entry into CD4+ cells. Saquinavir is a small molecule inhibitor of the HIV-1 protease enzyme, preventing maturation of infectious viral particles. Ritonavir is primarily used here as a pharmacokinetic enhancer, inhibiting CYP3A-mediated metabolism to increase plasma concentrations of saquinavir and maraviroc, but also has direct protease inhibitor effects. This regimen is used in antiretroviral-experienced adults and is considered when viral resistance or specific intolerance makes alternative regimens less suitable. Dose adjustments are required due to significant pharmacokinetic interactions among the components[1][2][3][7].